CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 501 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK9-IN-15
CAS:<p>CDK9-IN-15: potent CDK9 inhibitor, blocks P-TEFb phosphorylation, inhibits transcription, reduces mRNA, induces tumor cell apoptosis.</p>Fórmula:C16H11N3OSPureza:97.24%Forma y color:SolidPeso molecular:293.34CDK4/6-IN-12
CAS:<p>CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.</p>Fórmula:C12H10N6Forma y color:SolidPeso molecular:238.25FN-1501
CAS:<p>FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively).</p>Fórmula:C22H25N9OPureza:97.4%Forma y color:SolidPeso molecular:431.49CDK7-IN-20
<p>CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.</p>Fórmula:C30H26N6O3Forma y color:SolidPeso molecular:518.57CDK7-IN-13
CAS:<p>CDK7-IN-13: A potent pyrimidine-based CDK7 inhibitor, potential for various cancers. See CN114249712A.</p>Fórmula:C20H23F3N6OSPureza:99.22%Forma y color:SolidPeso molecular:452.5Indirubin-3'-monoxime-5-sulphonic acid
CAS:<p>Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.</p>Fórmula:C16H11N3O5SPureza:98%Forma y color:SolidPeso molecular:357.34BSJ-01-175
CAS:<p>BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.</p>Fórmula:C30H33ClN6O2Forma y color:SolidPeso molecular:545.08MDK6204
CAS:<p>MDK6204 is a selective inhibitor of CLK1 and CLK2.</p>Fórmula:C20H20N6OPureza:98%Forma y color:SolidPeso molecular:360.41XIE18-6
CAS:<p>XIE18-6 is a novel INK4C inhibitor that blocks p18 activity and promotes ex vivo expansion of human and murine hematopoietic stem cells.</p>Fórmula:C18H15NO6SPureza:99.712%Forma y color:SolidPeso molecular:373.38CDK4/6-IN-14
CAS:<p>CDK4/6-IN-14: potent CDK4/6 inhibitor, IC50s 10/16 nM, >60-fold selectivity over CDKs 1/2/7/9, selective across 205 kinases.</p>Fórmula:C24H27ClFN7OForma y color:SolidPeso molecular:483.97CDK8-IN-10
CAS:<p>CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.</p>Fórmula:C25H15ClF3N5O3Forma y color:SolidPeso molecular:525.87EGFR/HER2/CDK9-IN-3
CAS:<p>EGFR/HER2/CDK9-IN-3 inhibits EGFR (191.08 nM IC50), HER2 (132.65 nM), CDK9 (113.98 nM); shows anti-tumor effects.</p>Fórmula:C24H21N3O4S2Forma y color:SolidPeso molecular:479.57EGFR/HER2/CDK9-IN-1
CAS:<p>EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.</p>Fórmula:C23H21N3O3S2Forma y color:SolidPeso molecular:451.56CDK7-IN-2
CAS:<p>CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.</p>Fórmula:C26H39N7O3Forma y color:SolidPeso molecular:497.63CDK5 inhibitor 20-223
CAS:<p>CDK5 inhibitor 20-223 is a potent CDK2/CDK5 inhibitor,anti-Colorectal Cancer (CRC), inhibiting cell migration and inducing cell cycle arrest.</p>Fórmula:C19H19N3OForma y color:SolidPeso molecular:305.37CDK4/6-IN-7
CAS:<p>CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.</p>Fórmula:C18H18ClN5O3Forma y color:SolidPeso molecular:387.82CDK9-IN-14
CAS:<p>CDK9-IN-14: Potent CDK9 inhibitor, IC50=6.92 nM, effective on MV-4-11 cells and in vivo tumors, low toxicity, minimal side effects.</p>Fórmula:C21H23F2N3O4Forma y color:SolidPeso molecular:419.42CDK7-IN-12
CAS:<p>CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.</p>Fórmula:C20H19F3N6Forma y color:SolidPeso molecular:400.4CLK1-IN-2
<p>CLK1-IN-2: Metabolically stable, Clk1-selective inhibitor; IC50=1.7nM; useful in tumor, Duchenne MD, HIV-1, influenza research.</p>Fórmula:C16H12Cl2N2O2SForma y color:SolidPeso molecular:367.25Cdc7-IN-17
CAS:<p>Cdc7-IN-17 is a potent inhibitor of CDC7 with an IC 50 of <10 μM that can be used in cancer research [1].</p>Fórmula:C13H15N5OSForma y color:SolidPeso molecular:289.36
